ResultsIQ › Latest results › Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited Q2 FY27 earnings call summary
NSE: JAGSNPHARM · BSE: 507789
Earnings call of 29 Oct 2026, summarised by AI from the filing.
Standalone ₹81 cr (+9.3% YoY); consolidated ₹96 cr (+29%).
Key takeaways
- Q2 revenue Standalone ₹81 cr (+9.3% YoY); consolidated ₹96 cr (+29%).
- Acquisitions Aequitas and Group Pharma wellness portfolio integrated; first consolidated results reported.
- Growth driver Power brands: top 10 brands around 58% of revenue, nine in top 5 in their markets.
- Risk Hospital business is lower margin and will stay lower margin.
Jagsonpal Pharmaceuticals Limited Q2 FY27 results
As filed: Revenue ₹81.4 cr (+10% year on year), EBITDA ₹16.8 cr (+5% year on year), PAT ₹12.6 cr (−3% year on year), EBITDA margin 20.6% (−101 bps).
The Q2 FY27 score, against the company's own trend, is for premium members.
Earlier results and the share price after them
- Q1 FY27: Revenue ₹82.2 cr (+8% year on year), EBITDA ₹17.2 cr (+33% year on year), PAT ₹13.2 cr (+20% year on year), EBITDA margin 21.0% (+386 bps). Score 49 of 100, In line with trend. Revenue, EBITDA and profit growth were below the company's own trend. EBITDA margin rose 386 bps year on year. Share price after the results: +3.7% in 30 days (Nifty 500: +0.8%).
- Q4 FY26: Revenue ₹64.2 cr (+9% year on year), EBITDA ₹11.2 cr (+40% year on year), PAT ₹8.8 cr (+25% year on year), EBITDA margin 17.4% (+382 bps). Score 38 of 100, Below trend. Revenue, EBITDA and profit growth were in line with the company's own trend. EBITDA margin rose 382 bps year on year. Other income 27% of PBT. Revenue fell 12% from last quarter. Share price after the results: +2.6% in 30 days (Nifty 500: +0.6%).
- Q3 FY26: Revenue ₹73.0 cr (−1% year on year), EBITDA ₹16.3 cr (+2% year on year), PAT ₹11.0 cr (+4% year on year), EBITDA margin 22.3% (+68 bps). Score 41 of 100, In line with trend. Revenue, EBITDA and profit before exceptional items growth were below the company's own trend. EBITDA margin rose 68 bps year on year. Share price after the results: +5.4% in 30 days (Nifty 500: +2.5%).
- Q2 FY26: Revenue ₹74.0 cr (−1% year on year), EBITDA ₹16.0 cr (+7% year on year), PAT ₹13.0 cr (+18% year on year), EBITDA margin 21.6% (+162 bps). Score 41 of 100, In line with trend. Revenue, EBITDA and profit growth were below the company's own trend. EBITDA margin rose 162 bps year on year. Share price after the results: −4.7% in 30 days (Nifty 500: −0.4%).
- Q1 FY26: Revenue ₹76.0 cr (+25% year on year), EBITDA ₹13.0 cr (+30% year on year), PAT ₹11.0 cr (+120% year on year), EBITDA margin 17.1% (+71 bps). Score 65 of 100, Above trend. Revenue and profit growth were above the company's own trend; EBITDA growth was below it. EBITDA margin rose 71 bps year on year. Share price after the results: −9.4% in 30 days (Nifty 500: +0.2%).
- Q4 FY25: Revenue ₹59.0 cr (+37% year on year), EBITDA ₹8.0 cr (+167% year on year), PAT ₹7.0 cr (+75% year on year), EBITDA margin 13.6% (+658 bps). Score 57 of 100, In line with trend. Revenue and EBITDA growth were above the company's own trend; profit growth was in line with it. EBITDA margin rose 658 bps year on year. Other income 33% of PBT. Revenue fell 20% from last quarter. Share price after the results: −2.8% in 30 days (Nifty 500: +4.5%).
- Q3 FY25: Revenue ₹74.0 cr (+57% year on year), EBITDA ₹16.0 cr (+300% year on year), PAT ₹32.0 cr (+220% year on year), EBITDA margin 21.6% (+1,000 bps). Score 100 of 100, Above trend. EBITDA margin rose 1000 bps year on year. Not enough history for a trend yet: scored on growth alone.
Past price moves after results do not indicate future moves. Not a recommendation.
Jagsonpal Pharmaceuticals Limited earnings call, investor presentation and press release summaries
- Q2 FY27: Earnings call (29 Oct 2026), Results deck (28 Oct 2026), Results press release (28 Oct 2026)
- Q1 FY27: Earnings call (30 Jul 2026), Results deck (29 Jul 2026), Results press release (29 Jul 2026)
- Q4 FY26: Earnings call (28 Apr 2026), Results deck (27 Apr 2026), Results press release (27 Apr 2026)
- Q3 FY26: Earnings call (22 Jan 2026), Results deck (21 Jan 2026)
- Q2 FY26: Earnings call (4 Nov 2025), Results deck (3 Nov 2025)
- Q1 FY26: Earnings call (28 Jul 2025), Results deck (26 Jul 2025), Results deck (26 Jul 2025), Results press release (26 Jul 2025), Results press release (26 Jul 2025)
- Q4 FY25: Earnings call (7 May 2025), Results deck (6 May 2025)
Figures from the company's filings with NSE and BSE. Not investment advice.